|
Kilian Kelly
Chief Executive Officer and Managing Director
Cynata Therapeutics Limited
Cremorne, Victoria
Australia
|
Dr Kilian Kelly has over 20 years’ experience in biopharmaceutical research and development, including more than 13 years focussed on development of mesenchymal stem/stromal (MSC) based therapies. He is currently Chief Executive Officer and Managing Director at Cynata Therapeutics, an Australian clinical stage biotechnology company.
He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer, before taking on the role of CEO & MD in July 2023. At Cynata, he has overseen all stages of the development of the Cymerus™ induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide. He previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca.
Dr Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow and is a Graduate of the Australian Institute of Company Directors. He is also a member of the ISCT, the International Society for Stem Cell Research (ISSCR) and the Royal Pharmaceutical Society, and serves on the ISSCR Best Practices Regulatory Working Group and the Industry Interface Committee of the Center for Commercialisation of Regenerative Medicine (CCRM) Australia.
He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer, before taking on the role of CEO & MD in July 2023. At Cynata, he has overseen all stages of the development of the Cymerus™ induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide. He previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca.
Dr Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow and is a Graduate of the Australian Institute of Company Directors. He is also a member of the ISCT, the International Society for Stem Cell Research (ISSCR) and the Royal Pharmaceutical Society, and serves on the ISSCR Best Practices Regulatory Working Group and the Industry Interface Committee of the Center for Commercialisation of Regenerative Medicine (CCRM) Australia.